14 February 2019: Articles
Spindle Cell Sarcoma Mimicking Supraclavicular Lymph Node Metastasis of Breast Cancer
Challenging differential diagnosis
Se Hyun Paek ABDE 1, Kyoung Eun Lee DF 2, Han Su Kim DF 3, Joohyun Woo DF 1, Woosung Lim ADEG 1*DOI: 10.12659/AJCR.913581
Am J Case Rep 2019; 20:194-197
Abstract
BACKGROUND: Sarcomas can develop de novo or secondary to radiotherapy after or during breast cancer treatment. Diagnosis can be challenging, as such, a sarcoma is often missed on routine follow-up imaging and often presents with dermatologic findings.
CASE REPORT: Here, we present a case of a 45-year-old female who developed spindle cell sarcoma on her neck, which was mimicking supraclavicular lymph node metastasis of breast cancer.
CONCLUSIONS: Based on our report, we recommend a tissue biopsy with an immunohistochemistry profile when a mass suspicious for metastasis is found in patients with breast cancer.
Keywords: Breast Neoplasms, Sarcoma, Diagnosis, Differential, Neck, Neoplasms, Second Primary, Soft Tissue Neoplasms
Background
Differentiating a distant lesion mass in a breast cancer survivor can be challenging [1]. Many patients have been misdiagnosed and have undergone several months of treatment for a relapse of breast cancer [1,2]. Sarcomas developing as primary malignancies of the neck are a very rare complication after radiation therapy. Radiation-induced spindle cell sarcoma arising in the lymph nodes is very rare and has seldom been described in the literature. Here, we present a case of spindle cell sarcoma mimicking supraclavicular lymph node metastasis of breast cancer.
Case Report
A 37-year-old premenopausal Asian female was diagnosed invasive ductal carcinoma of right breast. The patient underwent a right breast conserving surgery and level II axillary lymph node dissection. The size of cancer was 2.2×1.5 cm and 1 sentinel lymph node was positive; stage II (T2N1M0). Immunohistochemistry was positive for both estrogen receptor (ER) and progesterone receptor (PR), and 1+ for Her-2 expression. The patient received 4 cycles of Adriamycin and cyclophosphamide (#4 AC), and this was followed by 4 cycles of paclitaxel (#4T) every 3 weeks and radiation therapy after chemotherapy. After chemotherapy, tamoxifen therapy was started and was continued for 5 years. After her operation, tumor recurrence was monitored regularly (every 6 month during the first 5 years and annually after 5 years) using tumor marker, mammography, and ultrasonography.
At 7 years and 8 months after the initial diagnosis, the patient developed a palpable mass on the right side of her neck. A neck ultrasonography revealed conglomerated hypoechoic nodules on the right supraclavicular area and neck level IV (Figure 1A). The fine needle aspiration (FNA) biopsy result showed malignant cells. A moderate hypermetabolic SUV 5.2 lesion on the right side of the neck at level IV was observed on the PET (positron emission tomography) study (Figure 1B). Based on the history and clinical findings, a supraclavicular lymph node recurrence of breast cancer was considered (since she had refused extended adjuvant endocrine therapy after the end of 5 years of tamoxifen therapy). An incisional biopsy was performed for definite diagnosis and immunohistochemistry results. Surprisingly, the surgical pathology results showed an undifferentiated spindle cell sarcoma. On microscope, atypical spindle cells were arranged in short and long fascicles, having tapering, hyperchromatic nuclei with eosinophilic cytoplasm amid fibrous stroma and significant mitotic figures (Figure 2A, 2B). Immunohistochemistry was positive for Vimentin (Figure 2C). It was negative for cytokeratin (CK), CD34, desmin, c-kit, smooth muscle actin (SMA) and S-100 protein (Figure 2D). These findings were consistent with undifferentiated spindle cell sarcoma. A decision was made to surgically remove (Rt. modified radical neck dissection: Rt. MRND) the tumor, and this would be followed by radiotherapy on the right side of the neck (right neck level III–IV, 66 Gy). On her recent follow-up examinations, all studies, including computed tomography, showed no evidence of any residual or metastatic lesion.
Discussion
Hormone receptor – positive breast cancers represent the majority of breast cancers around the world, affecting approximately 70% of women with breast cancer [3,4]. These cancers generally have a favorable prognosis; however, even though patients remain free of recurrence in the first 5 years, the risk of having the cancer recur elsewhere remains constant [5]. Approximately 33% of women with estrogen-receptor-positive breast cancer experience a recurrence, and over half of these recurrences arise more than 5 years after surgery [3–5]. Recurrence can be local, regional, or distant/metastatic [1].
Differentiating a distant lesion mass in a breast cancer survivor is sometimes difficult [1]. Neck lesion mass of our patient was developed more than 7 years after surgery. Because she had refused extended adjuvant tamoxifen endocrine therapy, the possibility of a recurrence of breast cancer was very high. However, we performed an incisional biopsy for immunohistochemical evaluation to select a therapeutic regimen. There is value in undertaking a biopsy of a suspected recurrence, not only to make a definitive diagnosis but because a breast metastasis may not have the same tumor biology as the original breast tumor and, therefore, may require different treatment [2,6,7].
Spindle cell sarcoma occurs on nearly any of the connective tissues of the body [8]. The name “spindle cell” comes from the shape of the cells when they are viewed through a microscope [9,10]. Symptoms vary depending on where the cancer is found, although nonspecific symptoms such as fatigue and a general feeling of malaise are common. This cancer is often not caught until it has spread because symptoms can be confused. Treatments may vary based on tumor size, progression of the disease, and the patient’s overall health status [11]. In most cases, after surgery, chemotherapy and/or radiation may be required. Unfortunately, the overall survival rate is less than 5 years since most spindle cell sarcoma cases are diagnosed in advanced stages [11,12].
Spindle cell sarcoma can develop for a variety of reasons [10]. Genetic predisposition is one factor, but it also may be caused by a combination of other factors, including injury and inflammation in patients that are already thought to be predisposed to such tumors. The development of spindle cells is a naturally occurring part of the body’s response to injury and radiotherapy can be one of the significant risk factor [13]. Radiation-induced sarcoma is a rare iatrogenic malignancy associated with poor outcomes [14]. Several studies have reported the incidence of radiation-induced sarcoma after breast cancer treatment [13–15], but radiation-induced spindle cell sarcoma arising in the supraclavicular lymph nodes has seldom been described in the literature. An early-stage radiation-induced sarcoma is difficult to identify by physical examination due to radiation-induced changes, often leading to a misdiagnosis as recurrent breast carcinoma, thereby delaying an accurate diagnosis [14]. FNA biopsy cannot provide definitive information about the histologic architecture of radiation-induced sarcoma nor can FNA biopsy provide adequate material for an immunohistochemical evaluation [15]. So, core needle or incisional biopsies are required. Patients with breast cancer, especially those who have taken radiation therapy, should be considered for a possible radiation-induced sarcoma. The risk of a radiation-induced sarcoma remains high for more than 10 years [13,14]. Our patient underwent 5000 cGy radiotherapy on the supraclavicular area, and this may have led to the development of a sarcoma on her neck.
Conclusions
Sarcomas can develop
References:
1.. Buonomo OC, Caredda E, Portarena I, New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes: PLoS One, 2017; 12; e0184680, pmid: 28922402
2.. Criscitiello C, Andre F, Thompson AM, Biopsy confirmation of metastatic sites in breast cancer patients: Clinical impact and future perspectives: Breast Cancer Res, 2014; 16; 205, pmid: 25032257
3.. Lumachi F, Brunello A, Maruzzo M, Treatment of estrogen receptor-positive breast cancer: Curr Med Chem, 2013; 20; 596-604, pmid: 23278394
4.. Lim E, Metzger-Filho O, Winer EP, The natural history of hormone receptor-positive breast cancer: Oncology (Williston Park), 2012; 26; 688-94, pmid: 22957400
5.. Bentzon N, During M, Rasmussen BB, Prognostic effect of estrogen receptor status across age in primary breast cancer: Int J Cancer, 2008; 122; 1089-94, pmid: 17960621
6.. Simmons C, Miller N, Geddie W, Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?: Ann Oncol, 2009; 20; 1499-504, pmid: 19299408
7.. Niikura N, Odisio BC, Tokuda Y, Latest biopsy approach for suspected metastases in patients with breast cancer: Nat Rev Clin Oncol, 2013; 10; 711-19, pmid: 24145987
8.. Jo VY, Fletcher CD, WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition: Pathology, 2014; 46; 95-104, pmid: 24378391
9.. Collini P, Sorensen PH, Patel S, Sarcomas with spindle cell morphology: Semin Oncol, 2009; 36; 324-37, pmid: 19664493
10.. Fisher C, Spindle cell sarcomas: Surg Pathol Clin, 2011; 4; 721-44, pmid: 26837645
11.. Feng L, Cai D, Muhetaer A, Spindle cell carcinoma: The general demographics, basic clinicopathologic characteristics, treatment, outcome and prognostic factors: Oncotarget, 2017; 8; 43228-36, pmid: 28591732
12.. Feng L, Wang M, Yibulayin F, Spindle cell sarcoma: a SEER population-based analysis: Sci Rep, 2018; 8; 5024, pmid: 29568070
13.. Kirova Y, Vilcoq JR, Asselain B, [Radiation-induced sarcomas after breast cancer: Experience of Institute Curie and review of literature]: Cancer Radiother, 2006; 10; 83-90, pmid: 16300982 [in French]
14.. Meng XY, Wu SK, Song ST, Clinical manifestations and radiological features may contribute to the early diagnosis of radiation-induced sarcoma after breast cancer: Clin Radiol, 2014; 69; 1228-34, pmid: 25266762
15.. Sheth GR, Cranmer LD, Smith BD, Radiation-induced sarcoma of the breast: A systematic review: Oncologist, 2012; 17; 405-18, pmid: 22334455
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






